tbuckley/cabot-search huggingface dataset:
Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma
Authors: Yong Yang, Jian-Zhong Cao, Sheng-Min Lan, Jun-Xin Wu, Tao Wu, Su-Yu Zhu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Yu-Jing Zhang, Yuan Zhu, Li-Ming Xu, Zhi-Yong Yuan, Shu-Nan Qi, Ye-Xiong Li
Journal: JAMA Oncology (2016)

The long-term survival benefit for radiotherapy (RT) in early-stage extranodal natural killer/T-cell lymphoma (NKTCL) is not known, and it is unclear whether improved locoregional control (LRC) translates into a survival benefit.To investigate the dose-dependent effect and potential survival benefits of RT on the basis of LRC improvements.Review of clinical data of patients with early-stage NKTCL at 10 institutions in China between 2000 and 2014. Radiotherapy dose as a continuous variable was entered into the Cox regression model by using penalized spline regression to allow for a nonlinear relationship between RT dose and events. Regression analysis was used to assess whether a linear correlation exists between LRC and progression-free survival (PFS) or overall survival (OS). Patients received chemotherapy (CT) alone, RT alone, or a combination. Chemotherapy alone was defined as 0 Gy.The association between LRC and OS or PFS.A total of 1332 patients (923 [69%] male; median age, 43 years [range, 2-87 years]) were reviewed. For patients treated with RT, median dose was 50 Gy (range, 10-70 Gy); 996 (86%) received at least 50 Gy, and 164 (14%) received 10 to 49 Gy. The risk of locoregional recurrence, disease progression, and mortality decreased sharply until 50 to 52 Gy. For patients receiving RT, high-dose RT (≥50 Gy) was associated with significantly better 5-year LRC (85% vs 73%; P < .001), PFS (61% vs 50%; P = .004), and OS (70% vs 58%; P = .04) than low-dose RT (<50 Gy). Improved LRC with high-dose RT was independent of the RT/CT sequence or initial response to CT. Radiotherapy yielded a dose-dependent effect on LRC (range, 41%-87%), PFS (18%-63%), and OS (33%-71%). Dose-response regression analysis revealed a linear correlation between 5-year LRC and 5-year PFS (correlation coefficient, r = 0.994, P < .001; determination coefficient, R2 = 0.988) or 5-year OS (r = 0.985, P = .002; R2 = 0.97), which was externally validated using published data.The optimal dose was 50 Gy for patients with early-stage disease. The improved LRC was associated with prolonged survival. These findings emphasize the importance of RT in optimizing first-line therapy, and provide evidence for making treatment decisions and designing clinical trials.
Molecular Mechanisms of JAK2V617F Oncogenic Activation: The JAK2- V617F Mutant Utilizes the SH2 Domain for Constitutive Kinase Activity in the Presence of Unstimulated Heterodimeric Cytokine Receptor.
Authors: Sivahari P Gorantla, Tobias Dechow, Rebekka Grundler, Christian Peschel, Justus Duyster
Journal: Blood (2008)
Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era
Authors: Chiara Rusconi, Maria Luisa Guerrera, Alessandra Tedeschi, Michelle Zancanella, Manuel Gotti, Michele Nichelatti, Sara Rattotti, Lara Crucitti, Marco Frigeni, Erika Meli, Paola Picardi, Anna Maria Frustaci, Roberta Sciarra, Vittorio Ruggero Zilioli, Periana Minga, Marco Paulli, Roberto Cairoli, Luca Arcaini
Journal: Blood (2015)
Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay
Authors: Connie Batlevi, Franck Rapaport, Andrew M. Intlekofer, Anne Reiner, Craig H Moskowitz, Steven M Horwitz, Andrew D Zelenetz, Lia Palomba, Alison J Moskowitz, John F. Gerecitano, Paul A Hamlin, Amanda R. Copeland, Matthew J Matasar, Craig S. Sauter, Anita Kumar, Ariela Noy, David J. Straus, Carol S. Portlock, Frederick Criscuolo, Jie He, Daniel Royston, Sohail Balasubramanian, Yekaterina Reznikovskaya, Janine D. Pichardo, Phil Stephens, Vincent Miller, Ross L. Levine, Venkatraman Seshan, Ahmet Dogan, Anas Younes
Journal: Blood (2015)
Decreased Transplant Related Mortality and Better Survival in HLA Matched (12/12 A, B, C, DRB1, DQB1, DPB1) Unrelated Bone Marrow Transplants.
Authors: Alain Filion, Pascale Loiseau, Vanderson Rocha, Ryad Tamouza, Sylvie Chevret, Marc Busson, Helene Esperou, Richard Traineau, Gerard Socie, Eliane Gluckman, Dominique Charron
Journal: Blood (2004)
Intermittent in Vivo Parathyroid Hormone (PTH) Treatment Results in Jagged 1 (Jag 1) Dependent and Independent Effects On Hematopoietic Stem Cells (HSCs)
Authors: Benjamin J Frisch, Ismat Shafiq, Rebecca L Porter, Jonathan M Weber, Julianne N Smith, Olga Bromberg, Miles Basil, Robinder S Dhillon, Edward M Schwarz, Laura M Calvi
Journal: Blood (2012)
AB0191 Durability of First Biologic Disease-Modifying Antirheumatic Drug Is Not Influenced by Initial/early DAS28
Authors: G. Rohekar, M. Movahedi, J.E. Pope, C. Bombardier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to assess among other things, response to biologic Disease-Modifyng Antirheumatic Drugs (bDMARDs) and conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD) therapy. <h3>Objectives</h3> The objective of this study was to look at a real-world population and determine if initial disease activity influences the durability of the first used biologic in RA treatment. <h3>Methods</h3> bDMARD-naïve RA patients were included if they started a biologic at baseline or at any time after entry into OBRI. For initial DAS, we used the DAS28 value between 6 months before and 3 months after the start of the first biologic, whichever was closer to the date of biologic use. Patients were censored at date of first biologic, or at date of last follow-up after initiation, whichever occurred first. Analysis was performed for all years of follow up, and also censored at 1.5 years (for investigating initial DAS impact). Persistence was defined as the length of time the patients continued to receive the drug, irrespective of change in dose, route, or addition of any other csDMARD or steroids. If the drug was stopped for &lt;60 days after which the patient restarted the same medication, it was considered a continuation and the duration was calculated accordingly. Patients were divided into three groups for analysis based on initial DAS28 score: remission (≤2.60), medium to high DAS28 (2.61–5.10) and severe (&gt;5.10). Survival was compared using KM curves. <h3>Results</h3> 563 patients were included. At 1 year, the survival probability was 0.78. The median survival of biologic was 57.8 (95% Confidence Interval: 42.2) months and with a mean survival of 44.5 (SE: 1.5) months. Patients who were on biologic monotherapy, with no concomitant csDMARD use, has worse persistence of their initial biologic. Figure 1 shows the KM Plot of survival on biologic stratified by DAS28. Despite the initial trend towards better survival associated with lower initial DAS, this was not statistically significant. Similarly, type of insurance (public/private) did not impact biologic survival. As seen in other studies, the only factor to impact longer persistence on initial biologic was use of a csDMARD with the bDMARD. <h3>Conclusions</h3> Early/initial DAS28 score did not impact patients9 persistence on their initial bDMARD, nor did insurance type. This suggests that initial DAS28 score does not influence the durability of the first bDMARD in active RA. Combination of csDMARD and bDMArD was more durable than bDMARD monotherapy. <h3>Disclosure of Interest</h3> None declared
THU0572 Relationship between Menstruation and Symptoms of Behçet's Syndrome:
Authors: G. Guzelant, Y. Ozguler, S.N. Esatoglu, G. Karatemiz, H. Ozdogan, S. Yurdakul, H. Yazici, E. Seyahi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is well known that menstruation triggers several conditions such as migraine, recurrent aphtous stomatitis and acne vulgaris in otherwise healthy individuals (1). It may exacerbate chronic autoimmune diseases and familial Mediterranean fever (FMF) (2–4). There is also one study that briefly mentions menstruation causes activation in Behçet9s syndrome (BS) (4). <h3>Objectives</h3> We investigated the relationship between menstruation and specifically the skin-mucosa lesions of BS. As controls, we studied FMF patients. <h3>Methods</h3> Premenopausal women with BS and FMF seen consecutively at the outpatient clinic of Cerrahpasa Medical Faculty at Istanbul, were interviewed. BS patients were asked whether they experienced increased skin-mucosa lesions during the menstrual period. A similar questionnaire assessing this time the frequency of serositis and fever attacks was given to the patients with FMF. As a control the participants were also asked whether they experienced headaches during the same period as well. <h3>Results</h3> A total of 140 BS patients with a mean age of 36±8 and mean disease duration of 9±6 years were studied. While 21 (15%) were off treatment, 103 (74%) were using colchicine and the remaining were using other immunosuppressive agents. As shown in the Table, among BS patients, 78 (56%) associated at least one symptom with menstruation. The most commonly reported symptom related with menstruation was the papulopustular involvement (50%), followed by oral (30%) and genital ulcers (21%) and nodular lesions (21%). We also studied 185 patients with FMF. Their mean age was 32±8 and mean disease duration was 12±8 years. All patients were using colchicine for a mean duration of 8±7 years. A total of 138 patients (75%) reported that their attacks overlapped with menstruation. These attacks included mostly peritonitis in 126 patients (68%), pleuritis in 102 (55%), and fever in 73 (40%). Among both BS and FMF patients, similar number of patients (41% and 41%, respectively) reported that menstruation triggered headaches. <h3>Conclusions</h3> This survey showed that, in about half of the patients with BS at least one skin mucosa lesion is exacerbated with menstruation. Most commonly reported were the papulopustular lesions. Menstruation had a stronger effect on FMF, triggering at least one symptom in about ¾ patients. The main limitation of the study was the self-reported assessment methodology, rather than a prospective diary assessment. Our findings provide further evidence that papulopustular lesions of BS and acne vulgaris are pathologically related (5). <h3>References</h3> Khanna N et al. Indian J Dermatol Venereol Leprol. 1991; Akar S et al. Rheumatol Int. 2006; Colangelo K et al. Rheumatology (Oxford). 2011; Karadag O et al. Rheumatol Int. 2013; Kutlubay Z et al. Clin Exp Rheumatol. 2015 <h3>Disclosure of Interest</h3> None declared
Hyperactivated mTOR Signaling Is a Characteristic Feature of High Risk Acute Lymphoblastic Leukemia and Can Be Effectively Targeted in a Preclinical NOD/SCID/huALL Xenograft Mouse Model
Authors: Md. Nabiul Hasan, Manon Queudeville, Sarah Mirjam Eckhoff, Manuel Herrmann, Simone Miller, Luca Trentin, Klaus-Michael Debatin, Lueder Hinrich Meyer
Journal: Blood (2011)
Comparison of B Cell Depletion Mediated by Intravenous (IV) Rituxan® and Rituxan Given Subcutaneous (SC) In Cynomolgus Monkeys
Authors: Christopher J Del Nagro, Cheng Ping Mao, Martin Brovarney, Karim Dabbagh, Herbert Birnboeck, Wolfgang F Richter
Journal: Blood (2010)
Resection of lung metastases from colorectal cancer: analysis of outcome and prognostic factors
Authors: A. Cassano, M.T. Congedo, E. D'Argento, C. Pozzo, E. Rossi, D. Nachira, A. Orlandi, G. Schinzari, M. Quirino, C. Bagalà, P. Granone, C. Barone
Journal: Annals of Oncology (2015)
Prestorage Leukoreduction of Transfused Red Cells Is Associated with Significant Ongoing 2–12 Month Survival Benefit in Cardiac Surgery Patients.
Authors: Lynn Boshkov, Grace Chien, Donna VanWinkle, Antony P. Furnary, Yingxing Wu, Gary Grunkemeier, Cynthia D. Morris
Journal: Blood (2006)
Prevalence of Anemia and Treatment Outcomes after Bariatric Surgery-a Retrospective Korean Study
Authors: Kim Kyoung Ha, Lee Min-Young, Han Jo Kim, Se Hyoung Kim, Hyun Jung Kim, Lee Sang-Cheol, Bae Sang Byung, Kim Chan-Kyu, Lee Kyu Taeg, Park Sung Kyu, Jong-Ho Won, Dae Sik Hong, Yong Jin Kim
Journal: Blood (2015)
In Vitro Expansion of Polycythemia Vera Progenitors Favors Expansion of Erythroid Precursors without JAK2 V617F Mutation.
Authors: Josef T. Prchal, Ko-Tung Chang, Jaroslav Jelinek, Yongli Guan, Amos Gaikwad, Jean-Pierre Issa, Enli Liu
Journal: Blood (2005)
Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency
Authors: Kha Le, Marvin Cohen, Yue Chen, Hyeryun Kim, Bruce Silver, Sam Agresta, Elizabeth Merica, Charles Kung, Penelope Kosinski, Lee Silverman, Scott Biller, Hua Yang
Journal: Blood (2015)
Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),
Authors: Haowei (Linda) Sun, Eshetu Atenafu, Richard Tsang, Vishal Kukreti, Michael Crump, John Kuruvilla
Journal: Blood (2011)
Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy
Authors: Daniel Johannes Kowalewski, Simon D. Walz, Linus Backert, Heiko Schuster, Susanne M. Rittig, Katja C. Weisel, Helmut R Salih, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S Stickel
Journal: Blood (2015)
Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant
Authors: Robert Collins, Hagop M. Kantarjian, Farhad Ravandi, Jenny Chen, Meghan Macaraeg, Vinoo Urity, Blake Pond, Abhijit Ramachandran, Jorge E. Cortes
Journal: Blood (2015)
Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.
Authors: Fermin M. Sanchez-Guijo, Eva Lumbreras, Patricia Morais, Juan-Luis Garcia, Norma C. Gutierrez, J.F. San Miguel, Consuelo del Canizo, Jesus M. Hernandez-Rivas
Journal: Blood (2007)
Comparison of Outcomes of Mismatched Related Stem Cell and Unrelated Cord Blood Transplants in Children with Severe T-Cell Deficiencies.
Authors: Juliana Folloni Fernandes, Vanderson Rocha, Myriam Labopin, Benedicte Neven, Andrew Gennery, Wilhelm Friedrich, Fulvio Porta, Cristina Diaz de Heredia, Donna A. Wall, Yves Bertrand, Paul Veys, Mary Slatter, Ansgar S Schulz, Ka Wah Chan, Michael Grimley, Mouhab F. Ayas, Tayfun Güngör, Wolfram Ebell, Carmem Bonfim, Krzysztof Kalwak, H. Bobby Gaspar, Paul Landais, Alain Fischer, Eliane Gluckman, Marina Cavazzana-Calvo
Journal: Blood (2009)
THU0284 Dynamics of B Lymphocyte Subsets in SLE Patients Treated with Rituximab
Authors: A.A. Mesnyankina, E.N. Aleksandrova, S.K. Soloviev, A.P. Aleksankin, S.I. Glukhova, A.A. Novikov, E.V. Suponitskaya, E.A. Aseeva, E.L. Nasonov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> to study B-cell subsets dynamics in SLE patients receiving rituximab (RTX) therapy with following 6 months observation. <h3>Methods</h3> The study included 16 SLE pts (1m/15f) with high (SLEDAI2K&gt;10 - 13 pts.) and moderate (SLEDAI2K&lt;10- 3 pts.) disease activity. Out of them 7 pts with lupus nephritis and 3 pts with neurolupus. RTX was administered to pts who failed to respond to glucocorticoids (GCs) and cytostatics (CTs). B-cells subsets were assessed before RTX administration (month 0), and at month 3 and month 6 of RTX therapy. RTX was administered at 500 to 2000 mg doses depending on disease activity. We investigated the absolute and relative number of CD19+ B cells, the total population of memory B cells (CD19+CD27+), "preswitch" (CD19+IgD+CD27+) and "postswitch" (CD19+IgD-CD27+) memory B cells, naive (CD19+IgD+CD27-) and transitional (CD19+IgD+CD10+CD38++CD27-) B cells, plasmablasts (CD19+CD38+++IgD-CD27+CD20-), short-lived plasma cells (CD19+CD38+), long-lived plasma cells (CD19+CD138+), and double-negative B-cells (CD19+CD27-IgD) were measured. All B cell subsets were analyzed by technique of multicolor flow cytofluorometry using panel of monoclonal antibodies to surface membrane markers of B-lymphocytes. <h3>Results</h3> Following initiation of RTX SLE clinical and lab activity indices have decreased in all 16 pts by month 3 and month 6 of follow up (SLEDAI-2K 0 month –Me 15 [11;19], 3 month -Me 7 [3;10], 6 month –Me 5 [4;9], <i>p</i>&lt;0.05), as well as decrease of absolute count CD19 B-cell subpopulation (0 month – Me 0,11 [0,0741; 0,2], 3 month - Me 0,0017 [0; 0,003], 6 month - Me 0,0045 [0,0005; 0,01], <i>p</i>&lt;0.05). B-cell repopulation by 6 month in 11 out of 16 pts was due to "naive" B-cells Me 0,00085 [0; 0,008], double negative Me 0,001 [0; 0,0025] and "postswitch" memory B-cells Me 0,0013 [0,0001; 0,003]. SLE exacerbation by 6 month was documented in 5 pts, in 3 out of them B-cell repopulation occurred. A correlation between baseline high SLE activity before RTX infusions (SLEDAI-2K 5 pts – Me 20 [18;24], 11 pts. Me 12 [8;12]) and SLE exacerbation at 6 month after initiation of RTM therapy (<i>p</i>&lt;0,05, r=0,54) was found. <h3>Conclusions</h3> Decrease in clinical and lab SLE activity was documented in all 16 pts by 3 month after one course of RTM therapy. In 3 out of 5 exacerbated pts at 6 month B-cell repopulation was found, but without significant correlation with counts of B-cells subpopulations during the whole follow up period. <h3>Disclosure of Interest</h3> None declared
Plans for improving care are being derailed by hospital deficits, GP leader warns
Authors: Adrian O’Dowd
Journal: BMJ (2016)

NHS transformation plans are being swept off course by acute care deficits that risk wasting the opportunity to improve patient services, doctors’ leaders have warned peers.

Royal college leaders warned that some health professionals working on sustainability and transformation plans (STPs)—the process for 44 areas in England to come up with proposals to improve health and save money (see http://bmj.co/stpMap)—are “blinkered” to long term change because of the severity of current financial problems among hospital trusts.

Representatives of several royal colleges appeared before the House of Lords’ NHS sustainability committee on 22 November to answer questions for the committee’s inquiry into the long term sustainability of the NHS.

Peers asked whether clinical commissioning groups (CCGs) were doing their job well enough to allow for …
Context Dependent Role of Polycomb Repressive Complex 2 in Acute Leukemia
Authors: Etienne Danis, Taylor Yamauchi, Kristen Echanique, Jessica Haladyna, Huafeng Xie, Nan Zhu, Simone Riedel, Kathrin M Bernt, Stuart H. Orkin, Scott A. Armstrong, Tobias Neff
Journal: Blood (2014)
FRI0509 Prevalence of Sarcoidosis and Autoinmune Disease in Not Necrotizing Granulomatosis
Authors: V. Alende, B. Sopeña, J. Cameselle Teijeiro, A. Gonzalez Quintela
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The diagnosis of not necrotizing granulomatosis (NNG) is very frequent in clinical practice. Physicians often focused their attention on sarcoidosis. However, there are many conditions that can cause this histological diagnosis, including infectous diseases, neoplasms or inflamatory diseases. There ara a few studies into the spectrum of pathologies that cause NNG; consequently, except for sarcoidosis, little information is available (1,2). <h3>Objectives</h3> This study has been designed to determine the prevalence of sarcoidosis and autoinmune diseases in not necrotizing granulomatosis. <h3>Methods</h3> We recolected all the tissue samples described as not necrotizing inflammation from 1 January 2010 to 31 december 2014 in the University Hospital of Santiago de Compostela. We recolected socio-demographic, analytical and tissue characteristics. We followed these patients and we described the final diagnosis. <h3>Results</h3> During the study period, a total of 290 samples of 207 patients were involved. The 50.7% were women, their mean age was 51,23 years. Concerning the sample origin, the distribution was as follows: skin 68 (32,9%), lymphadenopathy 55 (26,6%), Transbronchial biopsy 30 (14,5%), lung 12 (5,8%) and others 42 (20,2%). Concerning to final diagnosis, we found sarcoidosis 124 (59,9%); infectous diseases 16 (7,7%), including tuberculosis infection 8 (4,0%) and nontuberculous mycobacterial infection 3 (1,4%); Foreign body granulomatosis 13 (6,3%); neoplasms 12 (5,9%); autoinmune disease 6 (3,1%), 2 of them Wegener granulomatous (0,9%), 1 chronic polyarticular arthritis (0,5%), 1 Autoimmune hepatitis (0,4%), 1 systemic lupus erythematosus (0,5%) and 1 alopecia (0,5%); rosacea 3 (1,4%); Crohn disease 2 (0,9%); cheilitis 2 (0,9%) and amyloidosis 1 (0,5%). The diagnosis was not determinated in 12 patients (5,9%). <h3>Conclusions</h3> The prevalence of sarcoidosis in NNG is almost 50%. However, the autoinmune disease is considerably lower (2,5%), being Wegener granulomatous the most frequently reported autoinmue disease as it has been described in the literature. The alternative diagnosis most frequent was infectous diseases, including tuberculosis. In 90% of cases, final diagnosis was realized. <h3>References</h3> Nazarullah, A., Nilson, R., Maselli, D. J., &amp; Jagirdar, J. (2015). Incidence and aetiologies of pulmonary granulomatous inflammation: A decade of experience. Respirology, 20(1), 115–121. doi:10.1111/resp.12410 Woodard, B. H., Rosenberg, S. I., Farnham, R., &amp; Adams, D. O. (1982). Incidence and nature of primary granulomatous inflammation in surgically removed material. The American Journal of Surgical Pathology, 6(2), 119–29. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7102892/p&gt; <h3>Disclosure of Interest</h3> None declared
A Genome-Wide Linkage Scan of a Large Amish Pedigree with Von Willebrand Disease (VWD) Identified Several Chromosomal Regions That May Contain Potential Modifiers of Von Willebrand Factor (VWF) Levels and Disease Variability.
Authors: Jorge Di Paola, Mary Rickard, Jeffrey Murray, Trudy Burns, Kai Wang, Amy Shapiro
Journal: Blood (2006)
Making Decisions about Thromboprophylaxis in Pregnancy: Women's Values and Preferences
Authors: Shannon M Bates, Pablo Alonso-Coello, Mark Eckman, Kari A Tikkinen, Shanil Ebrahim, Luciane Cruz Lopes, Sarah D McDonald, Ignacio Neumann, Yuqing Zhang, Anne Flem Jacobsen, Elie A. Akl, Amparo Santamaria, Gordon H Guyatt
Journal: Blood (2014)
In Vivo Labeling of Dividing Chronic Lymphocytic Leukemia B Cells Suggests That CXCR4 and CD5 Define the Clonal Subfraction That Recently Proliferatead and Emigrated from a Solid Tissue
Authors: Carlo calissano, Rajendra Damle, Gregory Hayes, Elisabeth J Murphy, Marc Hellerstein, Barbara Sherry, Matthew S Kaufman, Steven L Allen, Kanti Rai, Nicholas Chiorazzi
Journal: Blood (2008)
Early Intervention in Minimal Residual Disease after Allogeneic Transplant for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Prolonged Survival by Imatinib.
Authors: Koichi Miyamura, Kodera Yoshihisa, Satoshi Skamaki, Shinji Nakao, Satoshi Sasaki, Toshiya Yokozawa, Chiaki Kato
Journal: Blood (2005)